SANAD II:左乙拉西坦、唑尼沙胺与拉莫三嗪治疗新诊断局灶性癫痫的有效性与成本效果
SANAD II 是一项开放标签、非劣效、多中心 4 期随机对照试验,纳入 990 例新诊断局灶性癫痫患者,比较左乙拉西坦或唑尼沙胺与拉莫三嗪作为一线治疗。ITT 分析中左乙拉西坦未达到非劣效标准,唑尼沙胺达到非劣效标准;PP 分析显示拉莫三嗪优于两者。拉莫三嗪成本效果最优,不支持将左乙拉西坦或唑尼沙胺作为一线治疗。
要点
- 左乙拉西坦在 ITT 分析中未达到相对拉莫三嗪的非劣效标准。
- 唑尼沙胺在 ITT 分析中达到非劣效,但 PP 分析显示拉莫三嗪更优。
- 拉莫三嗪成本效果最优,应继续作为局灶性癫痫一线治疗。
核心结论
- 研究结果不支持将左乙拉西坦或唑尼沙胺作为新诊断局灶性癫痫的一线治疗。
- 拉莫三嗪应继续作为局灶性癫痫的一线治疗,并作为未来试验的标准治疗。
研究设计与样本
- 开放标签、非劣效、多中心 4 期随机对照试验,在英国招募 5 岁及以上、发生两次或以上无诱因局灶性发作的患者。
- 990 名参与者按 1:1:1 随机分配至拉莫三嗪(n=330)、左乙拉西坦(n=332)或唑尼沙胺(n=328)。
主要发现
- 不良反应用药后报告率:拉莫三嗪组 108 例(33%),左乙拉西坦组 144 例(44%),唑尼沙胺组 146 例(45%)。
关键数值与推荐
- 成人及 12 岁以上初始维持剂量:拉莫三嗪 50 mg(晨)和 100 mg(晚),左乙拉西坦 500 mg 每日两次,唑尼沙胺 100 mg 每日两次。
临床怎么用
- 对于新诊断局灶性癫痫患者,拉莫三嗪应作为首选一线治疗。
- 左乙拉西坦和唑尼沙胺不宜作为一线治疗常规推荐。
局限性
- 研究为开放标签设计,参与者和研究者未设盲,可能影响主观结局报告。
- PP 分析排除了重大方案偏离和后续诊断为非癫痫的参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient evidence of clinical effectiveness and cost-effectiveness. We aimed to assess the long-term clinical effectiveness and cost-effectiveness of levetiracetam and zonisamide compared with lamotrigine in people with newly diagnosed focal epilepsy. METHODS: This randomised, open-label, controlled trial compared levetiracetam and zonisamide with lamotrigine as first-line treatment for patients with newly diagnosed focal epilepsy. Adult and paediatric neurology services across the UK recruited participants aged 5 years or older (with no upper age limit) with two or more unprovoked focal seizures. Participants were randomly allocated (1:1:1) using a minimisation programme with a random element utilising factor to receive lamotrigine, levetiracetam, or zonisamide. Participants and investigators were not masked and were aware of treatment allocation. SANAD II was designed to assess non-inferiority of both levetiracetam and zonisamide to lamotrigine for the primary outcome of time to 12-month remission. Anti-seizure medications were taken orally and for participants aged 12 years or older the initial advised maintenance doses were lamotrigine 50 mg (morning) and 100 mg (evening), levetiracetam 500 mg twice per day, and zonisamide 100 mg twice per day. For children aged between 5 and 12 years the initial daily maintenance doses advised were lamotrigine 1·5 mg/kg twice per day, levetiracetam 20 mg/kg twice per day, and zonisamide 2·5 mg/kg twice per day. All participants were included in the intention-to-treat (ITT) analysis. The per-protocol (PP) analysis excluded participants with major protocol deviations and those who were subsequently diagnosed as not having epilepsy. Safety analysis included all participants who received one dose of any study drug. The non-inferiority limit was a hazard ratio (HR) of 1·329, which equates to an absolute difference of 10%. A HR greater than 1 indicated that an event was more likely on lamotrigine. The trial is registered with the ISRCTN registry, 30294119 (EudraCt number: 2012-001884-64). FINDINGS: 990 participants were recruited between May 2, 2013, and June 20, 2017, and followed up for a further 2 years. Patients were randomly assigned to receive lamotrigine (n=330), levetiracetam (n=332), or zonisamide (n=328). The ITT analysis included all participants and the PP analysis included 324 participants randomly assigned to lamotrigine, 320 participants randomly assigned to levetiracetam, and 315 participants randomly assigned to zonisamide. Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission versus lamotrigine (HR 1·18; 97·5% CI 0·95-1·47) but zonisamide did meet the criteria for non-inferiority in the ITT analysis versus lamotrigine (1·03; 0·83-1·28). The PP analysis showed that 12-month remission was superior with lamotrigine than both levetiracetam (HR 1·32 [97·5% CI 1·05 to 1·66]) and zonisamide (HR 1·37 [1·08-1·73]). There were 37 deaths during the trial. Adverse reactions were reported by 108 (33%) participants who started lamotrigine, 144 (44%) participants who started levetiracetam, and 146 (45%) participants who started zonisamide. Lamotrigine was superior in the cost-utility analysis, with a higher net health benefit of 1·403 QALYs (97·5% central range 1·319-1·458) compared with 1·222 (1·110-1·283) for levetiracetam and 1·232 (1·112, 1·307) for zonisamide at a cost-effectiveness threshold of £20 000 per QALY. Cost-effectiveness was based on differences between treatment groups in costs and QALYs. INTERPRETATION: These findings do not support the use of levetiracetam or zonisamide as first-line treatments for patients with focal epilepsy. Lamotrigine should remain a first-line treatment for patients with focal epilepsy and should be the standard treatment in future trials. FUNDING: National Institute for Health Research Health Technology Assessment programme.
引用
- Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021. PMID: 33838757. doi:10.1016/S0140-6736(21)00247-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。